Related Experiment Video
Updated: Apr 16, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
Polymorphism characteristics of HIV-1 gpl20 and 5 hypervariable regions
Investigating human immunodeficiency virus type 1 (HIV-1) gp120, this study found that the V3 region has low variability, making it a promising target for AIDS vaccine development. CCR5 antagonists show potential for HIV treatment.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein 120 (gp120) is crucial for viral entry.
- Understanding gp120 polymorphism is key for effective vaccine and therapeutic strategies.
- Hypervariable regions of gp120 significantly influence viral escape and host immune responses.
Purpose of the Study:
- To analyze the polymorphism characteristics of HIV-1 gp120 and its five main hypervariable regions.
- To identify specific regions within gp120 suitable for vaccine development.
- To assess the implications of gp120 sequence diversity for HIV-1 tropism and treatment.
Main Methods:
- Analysis of length polymorphism, potential N-linked glycosylation sites (PNGSs), and sequence characteristics of gp120.
- Inclusion of global gp120 sequences from HIV-1 subtypes A, B, C, D, G, and H.
- Comparative analysis of variability across five hypervariable regions (V1-V5).
Main Results:
- The majority of HIV-1 gp120 sequences analyzed exhibited lengths of 496-515 amino acids with 21-30 PNGSs.
- The V3 hypervariable region demonstrated the lowest length polymorphism and heterogeneity, with fewer PNGSs compared to other regions.
- V1 and V4 regions showed high levels of length polymorphism and heterogeneity, along with more PNGSs.
- Most HIV-1 subtypes, excluding subtype D, possess consensus V3 sequences indicating R5 tropism, suggesting a prevalence of R5 strains.
Conclusions:
- Reducing polymorphism, heterogeneity, and PNGSs in specific gp120 hypervariable regions is crucial for developing effective AIDS vaccines.
- The conserved nature of the V3 region suggests its potential as a target for vaccine candidates.
- CCR5 antagonists may be highly effective for AIDS treatment due to the prevalence of R5-tropic strains.
More Related Videos
10:50Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding
Published on: September 15, 2010
13:41Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Related Concept Videos
Size and Structure of Viral Genomes
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Single Nucleotide Polymorphisms-SNPs
Leaky Scanning
Retroviruses